SCLC Clinical Trial
Official title:
Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer: A Single Arm Phase II Trial
NCT number | NCT04684017 |
Other study ID # | KS2039 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | May 1, 2019 |
Est. completion date | January 1, 2022 |
This is a phase II, open-label, single center study, aiming to investigate safety and efficacy of etoposide and carboplatin (administered intravenously) in combination with anlotinib (administered orally) in treatment-naive advanced NSCLC.
Status | Recruiting |
Enrollment | 29 |
Est. completion date | January 1, 2022 |
Est. primary completion date | September 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. According to the 8th edition of the AJCC/UICC TNM staging system for NSCLC, patients with extensive stage SCLC confirmed by histology or cytology and are confirmed to have at least one measurable lesion according to RECIST 1.1. 2. Without active brain metastasis 3. Previously treated with ICIs with progressive disease. 4. Age =18 years and =75 years; 5. ECOG PS score: 0 to 1 6. The main organs function is normal, that is, the following criteria met: good hematopoietic function, defined as absolute neutrophil count =1.5×109 /L, platelet count=100 ×109 /L, hemoglobin =90g/L [no blood transfusion or no erythropoietin (EPO) dependence within 7 days before enrollment]; biochemical test results should meet the following criteria: BIL < 1.25 times the upper limit of normal value (ULN); ALT and AST < 2.5 × ULN; in case of liver metastases, ALT and AST < 5 × ULN; Cr =1.5×ULN or creatinine clearance (CCr) =60ml/min; Coagulation function is good, INR and PT =1.5 times ULN; if the subject is receiving anticoagulant treatment, PT should be within the prescribed range of use of anticoagulant drugs; 7. Women of child-bearing age should agree to take contraceptive measures (such as intrauterine devices, contraceptives or condoms) during the study and within 6 months after the study; non-breast-feeding patients whose serum or urinary pregnancy test should be negative; male patients should agree to take contraceptive measures during the study and within 6 months after the study. 8. Patients are voluntarily enrolled into the study, sign the informed consent form and have good compliance. Exclusion Criteria: 1. Subjects with active CNS metastases are excluded. 2. Non-small cell lung cancer. 3. With obvious hemorrhage symptom 4. Patients with many factors affecting oral medication, such as dysphagia, gastrointestinal resection, chronic diarrhea and intestinal obstruction. 5. Combined with other tumors at the time of initial diagnosis. 6. Patients who have previously participated in other clinical trials and have not yet terminated the trial. 7. Patients who have acute infection that difficult to control. |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Chest hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Chest Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PFS | Time from enrollment to progression or death | Time from randomization to progression, assessed 9-11 months | |
Secondary | ORR | Patients who were assessed as partial response or complete response | 6-9 weeks | |
Secondary | OS | Time from enrollment to death of any cause | 13-15 months | |
Secondary | DCR | Patients who were assessed as partial response, complete response or stable disease | 6-9 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05026593 -
A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05903092 -
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00046787 -
Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer
|
Phase 2 | |
Suspended |
NCT04826341 -
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05655598 -
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
|
Phase 1 | |
Withdrawn |
NCT04677361 -
Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab
|
Early Phase 1 | |
Terminated |
NCT00522639 -
Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation
|
Phase 3 | |
Completed |
NCT03428607 -
Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]
|
Phase 2 | |
Recruiting |
NCT05546268 -
Study of Oral MRT-2359 in Selected Cancer Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT06116019 -
Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
|
||
Not yet recruiting |
NCT03244904 -
Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment
|
N/A | |
Completed |
NCT01713296 -
Pazopanib in Relapsed and Refractory Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04162041 -
Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05130255 -
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
|
Phase 1 | |
Recruiting |
NCT04686682 -
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05879068 -
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
|
Phase 2 | |
Completed |
NCT00346385 -
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02734004 -
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
|
Phase 1/Phase 2 |